abstract：:Gene therapy has now become a standard experimental approach for treating cancers that have failed conventional therapies. As the understanding of the molecular nature of carcinogenesis develops, new approaches are being taken to directly target tumor cells, thus bypassing the difficulties of killing cells that are re...

journal_title：Seminars in oncology

authors： Freeman SM,Whartenby KA,Freeman JL,Abboud CN,Marrogi AJ

更新日期：1996-02-01 00:00:00

abstract：:Distant metastasis is the major cause for therapeutic failures in Clinical oncology. Active immunotherapy in the adjuvant setting of patients with low tumor volume would contribute to further reduction of the remaining tumor and establish long-lasting immunity that could protect the patient from recurrence of disease....

journal_title：Seminars in oncology

authors： Gilboa E

更新日期：1996-02-01 00:00:00

abstract：:Phase I studies of CPT-11 (irinotecan) have been conducted in Europe, the United States, and Japan to determine the maximum tolerated dose (MTD) and the most appropriate intravenous administration schedule for further evaluation in phase II investigations. Diarrhea and/or neutropenia were the major dose-limiting toxic...

journal_title：Seminars in oncology

authors： Armand JP

更新日期：1996-02-01 00:00:00

abstract：:Adjuvant chemotherapy has a real but modest impact on the disease-free and overall survival of patients with breast cancer. Recent attempts to improve its effectiveness have focused on dose intensity and new agents. Sequential therapy maximized dose intensity while limiting overlapping toxicity. Sequential therapy usi...

journal_title：Seminars in oncology

authors： Hudis C,Seidman A,Raptis G,Fennelly D,Gilewski T,Baselga J,Theodoulou M,Sklarin N,Moynahan M,Surbone A,Currie V,Lebwohl D,Uhlenhopp M,Crown J,Norton L

更新日期：1996-02-01 00:00:00

abstract：:The activity of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been documented in untreated and previously treated metastatic breast cancer, including both patients with anthracycline-resistant disease and those with extensive pretreatment. Such activity has prompted investigations of...

journal_title：Seminars in oncology

authors： Dombernowsky P,Gehl J,Boesgaard M,Jensen TP,Jensen BV

更新日期：1996-02-01 00:00:00

abstract：:It is a truism that a better understanding of the biology of breast cancer should lead to improvements in diagnosis and therapy. Despite this, our significantly improved grasp of breast cancer biology has had little direct therapeutic impact to date. The technologies used to treat breast cancer (surgery, radiation the...

journal_title：Seminars in oncology

authors： Sledge GW Jr

更新日期：1996-02-01 00:00:00

abstract：:Because studies of breast cancer patients and their relatives provide statistical evidence for involvement of autosomal dominant genes, the identification of specific genetic effects has long been the focus of efforts to identify women at exceedingly high risk. BRCA1, a gene that confers greatly increased susceptibili...

journal_title：Seminars in oncology

authors： Cannon-Albright LA,Skolnick MH

更新日期：1996-02-01 00:00:00

abstract：:The results of recent clinical trials have shown that docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France), like paclitaxel (Taxol; Bristol-Myers Squibb Oncology, Princeton, NJ), has high levels of activity in patients with anthracycline-resistant breast cancer. Agents that are at least partially non-cross-resist...

journal_title：Seminars in oncology

authors： Ravdin PM

更新日期：1995-12-01 00:00:00

abstract：:Coelomic epithelial carcinoma of the ovary, the most common cause of death from cancer of the female genital tract in the United States, presents most commonly as advanced (stage III or IV) disease. Management consists of aggressive surgical cytoreduction followed by combination chemotherapy, until recently, a platinu...

journal_title：Seminars in oncology

authors： Thigpen T,Vance RB,McGuire WP,Hoskins WJ,Brady M

更新日期：1995-12-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 1-hour infusion potentially offers its recipients reduced toxicity, demonstrated efficacy, and greater ease of administration. To confirm this hypothesis, we undertook a phase I/II study of 1-hour, single-agent paclitaxel in 164 patients' refra...

journal_title：Seminars in oncology

authors： Hainsworth JD,Greco FA

更新日期：1995-12-01 00:00:00

abstract：:Data from various phase I/II studies of carboplatin in combination with paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) have suggested that the degree of thrombocytopenia seen is less than that expected when carboplatin is given alone. However, some studies also have suggested that the area under the p...

journal_title：Seminars in oncology

authors： Calvert AH,Boddy A,Bailey NP,Siddiqui N,Humphreys A,Hughes A,Robson L,Gumbrell L,Thomas H,Chapman F

更新日期：1995-10-01 00:00:00

abstract：:Combination antimicrotubule therapy with estramustine phosphate (EMP) and vinblastine has reproducible activity in metastatic hormone-refractory prostate cancer (HRPC) with an objective response rate of 31%. Although paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 24-hour infusion was inactive in HR...

journal_title：Seminars in oncology

authors： Hudes GR,Nathan FE,Khater C,Greenberg R,Gomella L,Stern C,McAleer C

更新日期：1995-10-01 00:00:00

abstract：:We studied the pharmacokinetics of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin administered in combination to 21 patients with advanced non-small cell lung cancer. Paclitaxel was administered as a 24-hour intravenous infusion at doses of 135 to 200 mg/m2. Carboplatin, dosed to a tar...

journal_title：Seminars in oncology

authors： Kearns CM,Belani CP,Erkmen K,Zuhowski M,Hiponia D,Zacharski D,Engstrom C,Ramanathan R,Trenn MR,Aisner J

更新日期：1995-10-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) represents almost three quarters of all cases of lung cancer. Most NSCLC patients present with either locally advanced inoperable disease, stage IV metastatic disease, or comorbid medical conditions that make them unsuitable for curative resection. Among NSCLC patients in the United ...

journal_title：Seminars in oncology

authors： Carney DN

更新日期：1995-08-01 00:00:00

abstract：:Inhibition of cellular DNA synthesis is the major action of gemcitabine. In cells, this drug is converted to its triphosphate (dFdCTP), which is incorporated into DNA and terminates DNA strand elongation. After incorporation of gemcitabine nucleotide into the DNA strand, one more deoxynucleotide is incorporated, and t...

journal_title：Seminars in oncology

authors： Huang P,Plunkett W

更新日期：1995-08-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to be an effective agent in the treatment of metastatic breast carcinoma. This multicenter randomized study compared paclitaxel 175 mg/m2 given as a 3-hour infusion every 3 weeks with mitomycin 12 mg/m2 given as an intravenous infusion ever...

journal_title：Seminars in oncology

authors： Dieras V,Marty M,Tubiana N,Corette L,Morvan F,Serin D,Mignot L,Chazard M,Garet F,Onetto N

更新日期：1995-08-01 00:00:00

abstract：:A dose-finding study was set up to identify the optimal dose of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin for phase II studies in patients with advanced chemotherapy-naive non-small cell lung cancer (NSCLC). The influence of drug sequence on the toxicity and pha...

journal_title：Seminars in oncology

authors： Giaccone G,Huizing M,Postmus PE,ten Bokkel Huinink WW,Koolen M,van Zandwijk N,Vermorken JB,Beijnen JH,Dalesio O,Pinedo HM

更新日期：1995-08-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated substantial single-agent activity against both minimally pretreated and resistant metastatic breast cancer. Evaluation of paclitaxel-based combinations has demonstrated appreciable activity, but also toxicity, for the paclitaxel/doxorubic...

journal_title：Seminars in oncology

authors： Kennedy MJ,Donehower RC,Rowinsky EK

更新日期：1995-08-01 00:00:00

abstract：:In a phase II Eastern Cooperative Oncology Group trial, single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was administered to 26 patients with advanced urothelial cancer who had not received prior systemic chemotherapy. Paclitaxel was given at a dose of 250 mg/m2 by 24-hour continuous infusi...

journal_title：Seminars in oncology

authors： Roth BJ

更新日期：1995-06-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) displays nonlinear pharmacokinetics in humans. Both peak plasma paclitaxel concentrations and areas under the curve (AUCs) of the concentration versus time profiles will change disproportionately to changes in dose. Models that accurately describe the pla...

journal_title：Seminars in oncology

authors： Kearns CM,Gianni L,Egorin MJ

更新日期：1995-06-01 00:00:00

abstract：:Surgery is the major curative treatment modality for patients with malignant disease. However, surgery also plays an important role in supportive and palliative care of cancer patients. In settings in which maintaining quality of life rather than prolongation of survival is the major goal of treatment, the potential m...

journal_title：Seminars in oncology

authors： Markman M

更新日期：1995-04-01 00:00:00

abstract：:Despite the high objective response rate of ovarian cancer to several reported platinum-based combination chemotherapy regimens, the majority of patients with advanced disease ultimately require consideration of a salvage regimen delivered for palliation of symptoms. A number of therapeutic strategies have been used i...

journal_title：Seminars in oncology

authors： Markman M

更新日期：1995-04-01 00:00:00

abstract：:One of the new agents intensively studied in the last decade for the treatment of metastatic breast cancer is vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France). This vinca alkaloid produces response rates comparable to other single agents in women with m...

journal_title：Seminars in oncology

authors： Abeloff MD

更新日期：1995-04-01 00:00:00

abstract：:From February 1985 to June 1993, 173 consecutive, previously untreated patients with small cell lung cancer received individualized treatment tailored to disease extent. Almost all patients (14 of 16) with stage I and II disease and 30 patients with operable stage III disease were submitted to surgery preceded or foll...

journal_title：Seminars in oncology

authors： Santoro A,Parra HS,Bidoli P,Angelidou M,Cataldo I,Salvini P,Valagussa P,Milani F,Ravasi G,Bonadonna G

更新日期：1995-02-01 00:00:00

abstract：:Most important is the physician's attitude, energy, and skill focused toward helping the patient through the difficulties in the last weeks of life. Many causes of nausea, dyspnea, and other troublesome symptoms can be effectively treated, and pharmacologic palliation is nearly always possible. A multidisciplinary tea...

journal_title：Seminars in oncology

authors： Storey P

更新日期：1994-12-01 00:00:00

abstract：:Quality of life (QOL) variables are increasingly included as end points in cancer therapy trials, supplementing such traditional end points as survival time in evaluating the effects of cancer treatments. Consensus has been reached that a number of QOL components (symptom status and physical, emotional, role, and soci...

journal_title：Seminars in oncology

authors： Moinpour CM

更新日期：1994-10-01 00:00:00

abstract：:Data from women with advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III or IV) were analyzed to evaluate the pharmacokinetic/pharmacodynamic relationships of carboplatin-based combination chemotherapy. With the equation area under the plasma concentration versus time curve (AUC) =...

journal_title：Seminars in oncology

authors： Egorin MJ,Reyno LM,Canetta RM,Jodrell DI,Swenerton KD,Pater JL,Burroughs JN,Novak MJ,Sridhara R

更新日期：1994-10-01 00:00:00

abstract：:We report an open, three-armed, multicenter study being carried out to assess the optimum treatment for acute and delayed emesis and nausea in patients undergoing highly emetogenic chemotherapy. Eighty-seven patients were randomized to receive tropisetron (Navoban; Sandoz Pharma Ltd, Basel, Switzerland), tropisetron p...

journal_title：Seminars in oncology

authors： Bruntsch U,Drechsler S,Eggert J,Gosse H,Ukena D,Imhoff W,Faerber L

更新日期：1994-10-01 00:00:00

abstract：:A phase I study of frequently administered carboplatin with recombinant human granulocyte colony-stimulating factor (filgrastim) has been performed in patients with newly diagnosed epithelial ovarian cancer. Recombinant human granulocyte colony-stimulating factor was administered at a dose of 5 micrograms/kg/d for day...

journal_title：Seminars in oncology

authors： Calvert AH,Lind MJ,Ghazal-Aswad S,Gumbrell L,Millward MJ,Bailey NP,Doré-Green F,Chapman F,Simmons D,Proctor M

更新日期：1994-10-01 00:00:00

abstract：:This phase I/II study was done to evaluate the safety and feasibility of two schedules of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) administered by 1-hour infusion in the outpatient setting. Fifty-six patients with advanced, refractory malignancies received one of two paclitaxel schedules by rand...

journal_title：Seminars in oncology

authors： Greco FA,Hainsworth JD

更新日期：1994-10-01 00:00:00

abstract：:The natural history of squamous cell head and neck cancer is well understood. Locoregional approaches to salvage therapy for this disease have curative potential, primarily because distant metastases are uncommon. Before proceeding with salvage treatment, however, clinicians should identify the extent of disease and d...

journal_title：Seminars in oncology

authors： Adelstein DJ

更新日期：1994-08-01 00:00:00

abstract：:Thus, many interesting and promising techniques are now available for the study of potential prognostic factors in esophageal carcinoma, and the results may supplement the information that is obtained by routine histopathologic analysis. It may become possible to define subgroups of patients with lower risk tumors, fo...

journal_title：Seminars in oncology

authors： Klimstra DS

更新日期：1994-08-01 00:00:00

abstract：:Squamous cell cancer of the cervix is a relatively drug-resistant tumor. Therefore, chemotherapy is predominantly reserved for cervical cancer patients with recurrent or refractory disease following surgery and/or radiation therapy or for patients who present with far advanced, incurable disease. Objective responses t...

journal_title：Seminars in oncology

authors： Alberts DS,Garcia DJ

更新日期：1994-08-01 00:00:00

abstract：:Previously untreated patients with stages I to IV, N0-3, M0 unresectable non-small cell lung cancer were randomized to arm I (conventional radiotherapy [RT], 60 Gy in 30 fractions over 6 weeks), arm II (accelerated RT, 60 Gy in 30 fractions over 3 weeks), arm III (conventional RT, as in arm I, plus carboplatin 70 mg/m...

journal_title：Seminars in oncology

authors： Bishop JF,Ball D,Crennan E,Ryan G,Davis S,Toner G,O'Brien P,Olver I

更新日期：1994-06-01 00:00:00

abstract：:The efficacy and toxicity of cisplatin/etoposide and carboplatin/etoposide combinations along with thoracic irradiation were prospectively assessed in patients with small cell lung cancer. Both combinations were equally effective. However, the carboplatin/etoposide regimen caused significantly less nausea, vomiting, n...

journal_title：Seminars in oncology

authors： Kosmidis PA,Samantas E,Fountzilas G,Pavlidis N,Apostolopoulou F,Skarlos D

更新日期：1994-06-01 00:00:00

abstract：:Based on rigorous interpretation of current evidence, systemic therapy has two roles in the management of carcinoma of the uterine cervix. In patients with advanced or recurrent disease, single-agent chemotherapy constitutes the treatment of choice. The most extensively studied agents are the platinum compounds. Eithe...

journal_title：Seminars in oncology

authors： Thigpen T,Vance RB,Khansur T

更新日期：1994-04-01 00:00:00

abstract：:In April 1990, the Argentine Group for Treatment of Acute Leukemia began a multicenter trial for the treatment of previously untreated acute myeloblastic leukemia patients who were under 21 years of age. Initial treatment consisted of an 8-day induction phase with cytarabine together with idarubicin on days 3 to 5 and...

journal_title：Seminars in oncology

authors： Sackmann-Muriel F,Fernández-Barbieri MA,Santarelli MT,Matus-Ridley M,Rosso A,Negri-Aranguren P,Cerutti I,Gomel M,Kvicala R

更新日期：1993-12-01 00:00:00

abstract：:Remarkable strides have been made in the management of infectious complications after bone marrow transplantation. Improved understanding of patterns of infection, the introduction of new antimicrobials, the advent of cytokines to enhance immune recovery, the development of better strategies to control graft-versus-ho...

journal_title：Seminars in oncology

authors： Wingard JR

更新日期：1993-10-01 00:00:00

abstract：:Knowledge of the pharmacokinetics of a drug is essential to the optimal design of the dose and schedule of chemotherapy protocols. As an extension, an understanding of the mechanism of drug action is necessary to construct the optimal strategy for combination chemotherapy. Nucleoside antimetabolites such as fludarabin...

journal_title：Seminars in oncology

authors： Plunkett W,Gandhi V,Huang P,Robertson LE,Yang LY,Gregoire V,Estey E,Keating MJ

更新日期：1993-10-01 00:00:00

abstract：:Bone marrow transplantation (BMT) preparative regimens consisting of busulfan (Bu) and cyclophosphamide (Cy) were developed as an alternative to preparative regimens based on total body irradiation (TBI). Animal studies demonstrated that Bu had a high level of myeloablative and antileukemic activity, but little immuno...

journal_title：Seminars in oncology

authors： Santos GW

更新日期：1993-08-01 00:00:00